secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001628280-23-006049
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology reports FY2022 cash of $105.3M; provides clinical updates for onvansertib
--------------------------------------------------------------------------------

- Cash, cash equivalents, and short-term investments $105.3M at Dec 31, 2022; projected runway into 2025.
- Total operating expenses $40.3M for FY2022, up $11.1M from FY2021; net cash used in operations $33.8M.
- Phase 1b/2 mCRC trial: ORR 35% (n=48), median PFS 9.3 months; bevacizumab-naïve subgroup ORR 69%, mPFS 13.5 months.
- Appointed Fairooz Kabbinavar as CMO, Tod Smeal as CSO, Charles Monahan as SVP Regulatory Affairs.
- Upcoming data readouts: mPDAC and SCLC in Q2/Q3 2023; TNBC in Q4 2023/Q1 2024; ONSEMBLE mCRC randomized data in Q3/Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828023006049/0001628280-23-006049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828023006049/crdf-20230302.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-006049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer